Introduction {#s1}
============

*Tupaia belangeri,* known as the tree shrew \[[@r6]\], belongs to the family Tupaiidae, which consists of 4 genera and 19 extant species \[[@r16]\]. *Tupaia* have been utilized in preclinical research, particularly in the fields of toxicology and virology, because of the high degree of genetic homology between several of their neuromodulator receptor proteins and those found in primates \[[@r8]\]. *Tupaia* have the potential to serve as animal models for various aspects of human behavior, including infant development, communication, and social structures \[[@r32]\]. In particular, chronic social stress in *Tupaia belangeri* is a natural and valid paradigm for studying behavioral, endocrine, and neurobiological changes that may underlie stress-related disorders such as depression \[[@r5],[@r6],[@r7],[@r8]\]. Although adult male *Tupaia* exhibit strong territoriality in their natural habitat, two males in visual and olfactory contact in a laboratory establish a stable dominant-subordinate relationship, where subordinates show distinct stress-induced alterations in behavior, physiology, and central nervous system activity \[[@r9]\]. The alterations exhibited by subordinate male *Tupaia* are similar to those observed in depressed human patients; in fact, *Tupaia* have been shown to be an effective animal model for the evaluation of antidepressant drugs \[[@r26]\].

*Tupaia belangeri* chronic social stress model is a natural and valid paradigm for studying the behavioral, endocrine, and neurobiological changes that may underlie stress-related disorders, such as depression \[[@r7], [@r8]\]. Intermittent cold stress (ICS) induced in mice is also used as a model of depression \[[@r22], [@r23]\]. ICS produces long-lasting thermal hyperalgesia and mechanical allodynia, particularly in female gonadectomized mice \[[@r23]\]. The aims of this study were to evaluate a new ICS model using *Tupaia* and to characterize the role of a key transcription factor in depression. Neuron-restrictive silencer factor (NRSF), also known as REST (RE1-silencing transcription factor) \[[@r4]\], is a transcriptional repressor of neuronal genes in non-neuronal cells. NRSF/REST interacts with other proteins, including the corepressors mSin3a and CoREST1, to form REST repressor complexes \[[@r29]\]; these interactions may play a critical role in the regulation of central nervous system activity and pain modulation. An amino acid alignment of NRSF/REST sequences indicates that, although *Tupaia* NRSF/REST shows higher homology to human NRSF/REST than to the mouse protein, the minimal repressor domains that may play a significant role in the interaction of NRSF/REST with mSin3B are completely conserved among the human, *Tupaia,* and mouse proteins ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Neuron-restrictive silencer factor/RE1-silencing transcription factor sequence alignment (amino acids 1--60) from *Homo sapiens*, *Tupaia belangeri*, and *Mus musculus*. Amino acids that differ from the human neuron-restrictive silencer factor/RE1-silencing transcription factor (NRSF/REST) sequence are shaded. The minimal repressor domain, which may contain a binding sequence for the paired amphipathic helix domains of Sin3 proteins, is highlighted in yellow. The *Tupaia* NRSF/REST sequence was predicted from whole genome sequences \[[@r32]\].) \[[@r24]\].

To address the role of NRSF/REST, Kouji *et al.* have designed low-molecular-weight compounds that mimic the alphα-helical structure of NRSF/REST \[[@r35]\], including C737 \[[@r10]\]. Based on known functions of NRSF/REST, C737 is expected to affect the expression of multiple neuronal proteins, including ion channels \[[@r15]\] and neurotransmitter synthetases and receptors \[[@r19], [@r20]\]. In this study, we aimed to evaluate the efficacy of C737 against ICS-induced weight loss and temperature changes in male and female *Tupaia*.

Materials and Methods {#s2}
=====================

Ethics statement
----------------

This study was carried out in strict accordance with both the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science and the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experimental protocols were approved by the institutional review boards of the regional ethics committees of Kagoshima University (VM12017, VM13043).

Animals
-------

Young adult male or female *Tupaia* (aged 6 months, summarized in [Table 1](#tbl_001){ref-type="table"}Table 1.Summary of *Tupaia* used in this studyNo. 40No. 35No. 41No. 36No. 42No. 39Age6 Months6 Months6 Months6 Months6 Months6 MonthsSexMaleFemaleMaleFemaleMaleFemaleTreatmentC737Agomelatine10% DMSO in PBS(-)) were bred in-house at Kagoshima University. Experiments were carried out according to standard guidelines for *Tupaia* care and use.

Drugs
-----

The compound C737 was designed and supplied by PRISM BioLab Co. (Yokohama, Japan). As a positive control, a group of animals was treated with the antidepressant agomelatine, a melatonin analogue that acts as an agonist for melatonin MT1 and MT2 receptors and a specific antagonist for serotonin (5-HT) 2C receptors \[[@r25]\]. C737 and agomelatine (Wako Pure Chemical Industries, Ltd., Osaka, Japan) were each dissolved in 10% dimethyl sulfoxide (DMSO) in water and administered at 10 mg/kg ip.

ICS exposure and drug treatment
-------------------------------

ICS exposure and constant cold stress were performed on 3 male and 3 female *Tupaia* ([Table 1](#tbl_001){ref-type="table"}) according to previously described methods \[[@r22]\]. Body weight, rectal temperature, drink volumes, and behavior were recorded each day for 5 days. We then placed the animals at room temperature (24 ± 2°C) for 30 min, followed by 4 ± 2°C for 30 min, 6 times consecutively. Rectal temperature and body weight were measured during these procedures and each day for the following 4 days. After 2 weeks, the animals were divided into 3 groups (n=2 per group): a solvent control group (10% DMSO in PBS\[-\]), a positive control group (agomelatine 10 mg/kg ip), and a C737-treated group (10 mg/kg ip). Treatments were administered once per day for 5 days. ICS was then induced as above. Body weight and rectal temperature were measured during these procedures and each day for the following 4 days.

Statistical analysis
--------------------

The Wilcoxon test was used to evaluate significant differences between groups. Statistical analyses were performed using GraphPad PRISM version 6.0e (GraphPad Software, San Diego, CA, USA). All *P*-values were two-sided and *P*\<0·05 was considered significant.

Results {#s3}
=======

Effect of C737 on outlook and neural behavior of the Tupaias
------------------------------------------------------------

The small compound C737 was designed to mimic the helical structure of the NRSF \[[@r35]\], and was expected to affect different aspects of neuronal function, including ion channels \[[@r15]\], neurotransmitter synthetases \[[@r19]\], and receptors \[[@r20]\]. The alignment of NRSF/REST protein (amino acid 1--60) was performed ([Fig. 1](#fig_001){ref-type="fig"}). Although Tupaia NRSF shows higher homology with human molecule than mouse one, the minimal repressor domains that may play significant role for interaction with mSin3B are completely conserved among human, Tupaia and mouse ([Fig. 1](#fig_001){ref-type="fig"}) \[[@r24]\].

We have evaluated the effect of C737 on their outlook and behavior of the Tupaias. The C737 administered intraperitoneally at 10 mg/kg caused no neural or other toxic effects in male or female Tupaias, and they did not show any abnormal food intake, expression, or behavior. The positive control is the antidepressant drug, agomelatine \[[@r25]\]. Agomelatine is a melatonin analogue that acts as an agonist for melatonin MT (1) and MT (2) receptors, and as a specific antagonist for 5-HT (2C) receptors. Administration of agomelatine did not cause neural or other toxic effects in the Tupaias.

Treatment of intermittent cold stress in Tupaia belangeri
---------------------------------------------------------

ICS produces long-lasting thermal hyperalgesia and mechanical allodynia, predominantly in female gonadectomized mice \[[@r23]\]. Therefore, we applied ICS to 3 males and 3 females Tupaia ([Table 1](#tbl_001){ref-type="table"}). We first brought them from room temperature (24 ± 2°C) for 30 min, to 4 ± 2°C for 30 min, 6 times consecutively ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.Experimental design for intermittent cold stress and drug treatments. (A) Body temperature and body weight of each animal were measured for 5 days before intermittent cold stress (ICS) induction. ICS treatments were repeated 6 times; body weight and temperature were measured during and after ICS. (B) Animals were then treated with C737, agomelatine, or solvent control once per day for 5 days and then exposed to ICS. Body temperature and body weight were measured throughout the experiment.). During these stresses, we measured body temperature and body weight, and indicated a compound untreated control in [Figs. 2](#fig_002){ref-type="fig"} and[3](#fig_003){ref-type="fig"}. After 2 weeks, the Tupaias were divided into 3 groups, solvent control group (10% DMSO in 90% PBS (−)), positive control group (agomelatine 10 mg/kg/ip administrated), and C737 (10 mg/kg/ip) treated group ([Fig. 2B](#fig_002){ref-type="fig"}).

Effects of C737 and agomelatine on Tupaia behavior following ICS
----------------------------------------------------------------

To evaluate the effects of C737 and agomelatine on ICS, each drug was administrated at 10 mg/kg ip each day for 5 days before ICS treatment. Neither drug caused neural or toxic effects nor resulted in abnormal food intake, expression, or behavior in male or female *Tupaia*. In female *Tupaia*, ICS-induced body weight decreases were prevented more effectively by C737 treatment ([Fig. 3B](#fig_003){ref-type="fig"}Fig. 3.Changes in body weight and body temperature in ICS-exposed female *Tupaia*. Body temperature (A, C, E) and body weight (B, D, F) of female *Tupaia* exposed to ICS with and without pre-treatment with C737 (animal No. 35; A, B), agomelatine (No. 36; C, D), or solvent control (No. 39; E, F). Shaded regions and arrows indicate the ICS exposure period. \* *P*\<0.05 (Significant difference between with or without C737).) than by agomelatine treatment ([Fig. 3D](#fig_003){ref-type="fig"}), although both treatments prevented weight decreases more effectively than the solvent control ([Fig. 3F](#fig_003){ref-type="fig"}). Pre-treatment with C737 or agomelatine showed no significant effects on ICS-induced decreases in body temperature ([Figs. 3](#fig_003){ref-type="fig"}A,[3](#fig_003){ref-type="fig"}C and[3](#fig_003){ref-type="fig"}E).

In male *Tupaia*, ICS-induced decreases in body temperature were more pronounced in the C737 and agomelatine-treated animals after 6 cold treatments, respectively ([Figs. 4A and 4C](#fig_004){ref-type="fig"}Fig. 4.Changes in body weight and body temperature in ICS-exposed male *Tupaia*. Body temperature (A, C, E) and body weight (B, D, F) of male *Tupaia* exposed to ICS with and without pre-treatment with C737 (animal No. 40; A, B), agomelatine (No. 41; C, D), or solvent control (No. 42; E, F). Shaded regions and arrows indicate the ICS exposure period.). C737 was more effective than agomelatine at reducing ICS-induced weight loss ([Figs. 4B and 4D](#fig_004){ref-type="fig"}); however, its effects were similar to those observed in the solvent control-treated animal ([Fig. 4F](#fig_004){ref-type="fig"}).

Discussion {#s4}
==========

Non-rodent animal models may be used to characterize the molecular mechanisms of neurological diseases with epigenetic influences such as depression and to effectively evaluate treatments. *Tupaia belangeri* was previously classified as a primate but is now classified within the order Scandentia \[[@r36]\] and family Tupaiidae. *Tupaia* have been used in the characterization of social stress \[[@r8]\], depression \[[@r7]\], and for the evaluation of antidepressant drugs \[[@r26]\]. In the present study, treatment with the antidepressant agomelatine partially prevented ICS-induced decreases in body weight in a female *Tupaia*; however, this effect was more pronounced in an animal treated with C737.

The inhibitory effects of C737 and agomelatine on ICS-induced weight loss were observed only in female *Tupaia*. Interestingly, ICS induces painful effects similar to those of fibromyalgia, a disorder that primarily affects women \[[@r33]\]. Consistent with this pattern, ICS-induced allodynia is more commonly observed in females in a gonadectomized mouse model of fibromyalgia \[[@r23]\]. The exact molecular mechanism responsible for these effects should be addressed in future studies.

NRSF/REST is a transcriptional repressor of more than 1,000 neuron-specific genes in mammalian non-neuronal cells \[[@r3], [@r28]\]. Many target genes of NRSF/REST \[[@r30]\] encode proteins with neuronal functions, including ion channels (e.g., sodium channel type II \[[@r15]\]), neurotransmitter synthetases (e.g., choline acetyltransferase \[[@r18], [@r19]\] and dopamine β-hydroxylase \[[@r11], [@r12]\]) and receptors (e.g., the muscarinic acetylcholine receptor M4 \[[@r20], [@r34]\], the nicotinic β2 receptor subunit \[[@r2]\], and the *N*-methyl-D-aspartate receptor type 1 \[[@r1]\]), synaptosomal proteins (e.g., synapsin I \[[@r17], [@r27]\]), neuronal cell adhesion molecules (e.g., neuron-glia cell adhesion molecule \[[@r14]\] and L1 \[[@r13]\]), neuronal cytoskeletal proteins (e.g., tubulin βIII \[[@r3], [@r30]\]), neurotrophic factors (e.g., brain-derived neurotrophic factor \[[@r31]\]), and neuronal growth-associated proteins (e.g., SCG10 \[[@r21]\]). A recent study of NRSF/REST-deficient mice by Anderson and colleagues \[[@r3]\] revealed that the loss of NRSF/REST *in vivo* derepresses the expression of several of its target genes, including SCG10 and tubulin βIII. Loss of NRSF/REST disrupts neural development and ultimately leads to embryonic lethality, although the specific cause of death is unknown. Despite its prominent role in neural development, however, the transcriptional mechanisms underlying neuron-specific gene repression by NRSF/REST are largely unknown.

NRSF/REST expression is increased in primary sensory nerve fibers after nerve disorder because of reduced histone acetylation of pain-related genes. NRSF/REST upregulation silences the expression of the C fibrotic desensitizing, which is a characteristic of neuropathic pain that is reported to induce morphine resistance \[[@r37]\]. ICS-related pain (or allodynia/hyperalgesia) could link the effects of NRSF/REST on neuropathic pain, suggesting its possible effects on ICS \[[@r37]\]. Compounds that bind to the paired amphipathic helix domain of mSin3B, a binding partner of NRSF/REST, do not show pain inhibitory activity. Therefore, the NRSF/REST domain that interacts with mSin3B, which is highly conserved among *human*, *Tupaia* and *mouse*, may be a potential target for new compounds. The findings of this study provide interesting non-rodent preclinical data on the effects of C737, a new compound that mimics the structure of NRSF/REST and can block its interaction with mSin3b and other molecules, on stress-induced abnormalities. Further studies are in progress to investigate the effects of C737 in the *Tupaia* induced stress model of disorders such as depression. During the course of experiment, tupaia body weight accidentally decrease by urination or evacuation in some points, therefore, evaluation of significance of drug treatment should be judged in multiple points.

In conclusion, the results of this study highlight the utility of *Tupaia belangeri* as a new animal model of ICS. We also show that C737 exerted protective effects against ICS-related weight loss in female *Tupaia*, as did the antidepressant agomelatine. Future studies are required to characterize the sex specificity of these effects and to investigate the efficacy of C737 as a novel antidepressant drug.
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